Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 InfectionSARS-CoV-2 감염에서 중화와 비교한 항체 의존성 Fc 매개 바이러스 진입 평가Article Published on 2022-05-312022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] Alpha antibody antibody dependent enhancement B.1.1.7 B.1.351 B.1.617.2 Beta characterization collected concern convalescent plasma coronavirus coronavirus – COVID-19 correlated Delta determine evaluated Fc-mediated virus entry functional Gamma HEK293 cell HEK293 cells IgM in vivo individuals infecting neutralization neutralization activity neutralization potency neutralization titer Neutralizing P.1 pandemic peaked plasma plasma dilution plasma IgG plasmas pseudovirus SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 strain SARS-CoV-2 variants significantly significantly higher significantly lower spike (S) protein titers variant variant of concern viral entry virus virus entry viruses VoC waned Washington while [DOI] 10.3389/fimmu.2022.901217 PMC 바로가기 [Article Type] Article
Lebanese SARS-CoV-2 genomics: 24 months of the pandemicArticle Published on 2022-05-202022-10-04 Journal: Virus research [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, [키워드] accessory proteins addition Alpha analyzed clade clades Clustering collected country Course COVID-19 COVID-19 pandemic distribution event FIVE Genome genomic GISAID Health highlight Lebanon lineages marker measure Mutation mutations outbreak pandemic Phylogenetic analysis Phylogenetic relationship SARS-CoV-2 SARS-CoV-2 strain sequenced Sequencing Seven Spread strain Strains Two years vaccination variant variants of concern [DOI] 10.1016/j.virusres.2022.198824 PMC 바로가기 [Article Type] Article
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 Research Published on 2022-05-162022-10-05 Journal: Nature [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] addition Antiviral Antiviral compound antiviral drug B.1.1.529 characterization chimeric COVID-19 delta variant dominant effective Effectiveness evaluated expressing hamster hamsters individual isolate less Lineage mice molnupiravir monoclonal antibody Mutation Neutralizing activity omicron organ pathogenicity plasma raised recipient reduction in REGN10933 REGN10987 Replication replicative restrict rodent S309 SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 strains Strains susceptibility the spike protein therapeutic Vaccine Vaccines variant variants viral infection [DOI] 10.1038/s41586-022-04856-1 [Article Type] Research
Strain wars 2: Binding constants, enthalpies, entropies, Gibbs energies and rates of binding of SARS-CoV-2 variants스트레인 워즈 2: 결합 상수, 엔탈피, 엔트로피, 깁스 에너지 및 SARS-CoV-2 변이체의 결합 속도Article Published on 2022-05-012022-09-11 Journal: Virology [Category] COVID19(2023년), SARS, 변종, [키워드] Alpha strain B.1.1.529 Beta Beta strain binding binding constant calculated changes in characterized competition COVID-19 pandemic Delta Delta strain explained Gamma Gamma strain greater Hu-1 strain Interference kinetic Mutant strains mutate mutated Mutation mutations omicron Omicron strain. phenomenon RNA viruses SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 virus shown Standard strain Strains suppression the SARS-CoV-2 virus thermodynamic virus wild type [DOI] 10.1016/j.virol.2022.03.008 PMC 바로가기 [Article Type] Article
A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting외래 환자 환경에서 경증에서 중등도의 COVID-19가 있는 피험자를 대상으로 한 RD-X19의 무작위, 대조, 타당성 연구Randomized Controlled Trial Published on 2022-05-012022-09-11 Journal: Clinical and translational science [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] adverse events Alpha assessment assessments baseline benefit Beta clinical assessment clinical assessments Clinical outcome coronavirus disease Coronavirus disease 2019 COVID-19 cytokine Cytokines Device dose doses double-blind enrolled epithelial Epithelial Tissue expression feasibility Feasibility study greater IL-1α IL-1β immune in vitro internal Local Local application log log rank test Measures median time Mild mild to moderate Mild-to-moderate moderate Moderate COVID-19 oral cavity oropharynx outcome measure Outpatient outpatients positive Randomized reaction reduction Replication Saliva SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 strain Severe acute respiratory syndrome shown Signs and symptoms subject sustained Symptom tested the mean tissue tissues treated Treatment variants Viral load visible light [DOI] 10.1111/cts.13249 PMC 바로가기 [Article Type] Randomized Controlled Trial
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort studyCOVID-19에서 회복된 사람들의 감염 1년 후 SARS-CoV-2-특이 항체 및 T-세포 반응: 종단 코호트 연구Article Published on 2022-05-012022-09-11 Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, 치료기술, [키워드] Academy age analysed antibody Antibody Response antibody titres B.1.351 B.1.617.2 Beta Beta variant breadth caused center Chinese collected communicable disease Communicable Disease Diagnosis COVID-19 Critical cross-reactive cytokine cytokine profile D614G D614G variant delta variant Delta variants detect detectable discharged disease disease severity ELISA ELISPOT enrolled enzyme evaluated Follow-up Follow-up visit follow-up visits foundation humoral humoral and T-cell response ICS IFN-γ IFNγ IgA IgG antibodies IgG antibody IgM IL-2 immune immune response In-vitro individual individuals Infection initial interferon interferon γ interleukin interleukin-2 intracellular cytokine staining longitudinal cohort study magnitude Medical Research Council Medical Sciences memory memory immune response memory T-cell response memory T-cell responses microneutralisation assay natural Necrosis neutralising Neutralising Antibodies neutralising antibody neutralising antibody response Neutralising antibody responses neutralising antibody titre neutralising antibody titres no difference not disrupted participant Patient patients patients with moderate PBMC PBMCs plasma plasma sample plasma samples Protein Receptor-binding domain recovered patient recovered patients recruited reduce reduced reducing reduction Reinfection remained retained robustness SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleoprotein SARS-CoV-2 strain SARS-CoV-2 viral SARS-CoV-2-specific T-cell response Science severe disease spike Spike protein subset symptom severity Symptoms T-cell Response T-cell responses tested the interferon the receptor-binding domain the SARS-CoV-2 titre TNFα tumour necrosis factor Tumour Necrosis Factor α variant variants variants of concern Viral proteins viral strain viral strains Wuhan Wuhan, China [DOI] 10.1016/S2666-5247(22)00036-2 PMC 바로가기 [Article Type] Article
MALVIRUS: an integrated application for viral variant analysisMALVIRUS: 바이러스 변이체 분석을 위한 통합 애플리케이션Article Published on 2022-04-192022-09-11 Journal: BMC Bioinformatics [Category] COVID19(2023년), SARS, 변종, [키워드] Analysis assist available data being Complete COVID-19 pandemic dataset demonstrated Effectiveness Efficiency Genotype genotyped genotyping GISAID globe Illumina Lineage Lineage classification NCBI produced provided recall required SARS-CoV-2 SARS-CoV-2 strain Sequence analysis sequencing data Spread supported Test the SARS-CoV-2 variant variants Variation variations viral strain viral strains viral variant virus [DOI] 10.1186/s12859-022-04668-0 PMC 바로가기 [Article Type] Article
Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection Research Published on 2022-04-192022-10-05 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] activity addition Breakthrough infection Cell complex COVID-19 DNA topoisomerase downstream entry of SARS-CoV-2 expression profiling facilitate human airway epithelial human lung in viral Infection inhibit inhibit SARS-CoV-2 inhibitor interact Interaction membrane protein modulate offer overcome plasma membrane Post-vaccine promote Protein receptor receptors reduced SARS-CoV-2 strain Support target the SARS-CoV-2 therapeutic target therapy tissues viral entry [DOI] 10.1038/s41598-022-10293-x [Article Type] Research
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2mRNA-1273 및 Ad26.COV2.S 백신은 SARS-CoV-2의 B.1.621 변이체로부터 보호합니다.Clinical and Translational Article Published on 2022-04-152022-09-14 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 진단, [키워드] in vivo vaccine efficacy studies Abstract ACE2 acute respiratory syndrome Ad26.COV2.S Ad26.COV2.S vaccine adenoviral-vectored vaccine AMED animal models B.1.621 center Context coronavirus D614G D950N development disease E484K Efficacy evaluated finding funding greater transmissibility hamster hamsters High dose Immunity immunization induce Infectious disease Infrastructure Innovation Japan Johnson & Johnson Lung infection Lung pathology mice Moderna mRNA vaccine mouse mRNA-1273 mRNA-1273 vaccine N501Y Neutralizing antibodies neutralizing antibody New NIAID NIH omicron P681H Program PROTECT reduced response SARS-CoV-2 SARS-CoV-2 strain Serum neutralizing antibody spike mutation supported Syrian hamster transgenic mice Vaccine variant variant of SARS-CoV-2 variants of SARS-CoV-2 viral variant virus WA1/2020 weight loss [DOI] 10.1016/j.medj.2022.03.009 PMC 바로가기 [Article Type] Clinical and Translational Article
Dynamics of COVID-19 in Amazonia: A history of government denialism and the risk of a third waveResearch article Published on 2022-04-012022-10-05 Journal: Preventive Medicine Reports [Category] 변종, [키워드] applied Brazil Combination Contact coronavirus COVID-19 deaths delta variant Dynamics Epidemiology evaluated explain First wave FIVE Gamma variant generate global pandemic Government greater transmissibility group Hospitalization hospitalizations hypothese hypotheses Immunity Immunity loss indicate Infection Lineage Loss Manaus Measures Multi-strain SEIRS model P.1 pandemic population immunity predominant public health public health policy reached Reinfection remained responsible risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain second wave strain the SARS-CoV-2 threshold Transmissibility transmission rate vaccination vaccination rate Vaccine variant virus [DOI] 10.1016/j.pmedr.2022.101752 [Article Type] Research article